Oncothyreon, Inc. (NASDAQ:ONTY)

CAPS Rating: 4 out of 5

Results 1 - 12 of 12

Recs

0
Member Avatar pchop12316 (85.88) Submitted: 8/20/2014 10:24:52 AM : Outperform Start Price: $2.29 ONTY Score: +2.82

attractive at this price point

Recs

0
Member Avatar whoodatstockhot (91.09) Submitted: 9/25/2013 12:00:39 PM : Outperform Start Price: $2.28 ONTY Score: -13.87

Strong probability tecemotide succeeds in stage 3 trial-- which would push shares above the $4 dollar mark. Also, nice chance of Merck buyout before then, which would provide significant upside. Potential homerun in the making here.

Recs

0
Member Avatar fatmoneyrz (98.06) Submitted: 9/25/2013 9:52:01 AM : Outperform Start Price: $2.24 ONTY Score: -12.64

Big upside with START2. $3+ valuation in near-term.

Recs

0
Member Avatar stainsolution (48.69) Submitted: 4/4/2012 8:53:38 PM : Outperform Start Price: $4.20 ONTY Score: -87.30

Cancer Bio. Hammered recently. Willing to buy here/ hold for the Ph III run up.

Recs

0
Member Avatar RBuskey106 (52.74) Submitted: 3/14/2012 10:46:05 PM : Outperform Start Price: $4.84 ONTY Score: -94.00

Waiting for Ph 3 stimuvax results...thinking stock may have bottomed.

Recs

1
Member Avatar ccatania13 (< 20) Submitted: 11/21/2011 12:17:13 AM : Outperform Start Price: $7.08 ONTY Score: -133.19

Another stock getting ready to break out. This stock is undervalued right now, and it is prime for the picking. Get ready for shooting star.

Recs

2
Member Avatar siliconvalleyboy (< 20) Submitted: 5/23/2011 1:46:14 AM : Outperform Start Price: $5.56 ONTY Score: -109.16

Very compelling early data from phase II. Existing trial is continuing and data is expected late Q2. Very strong pipeline ahead of them. 1 small molecule with very good chemistry AND a more powerful version of the existing drug, this new drug is not partnered and its value will go up tremendously with the approval, if and when it happens.

Recs

0
Member Avatar alcear (29.36) Submitted: 4/26/2011 10:06:05 AM : Outperform Start Price: $3.50 ONTY Score: -91.89

Oncothyreon ONTY Rodman & Renshaw Mkt Outperform $10 (as of 4/26/11)

Recs

0
Member Avatar RSorak (< 20) Submitted: 4/7/2011 10:12:01 AM : Outperform Start Price: $5.53 ONTY Score: -131.75

See slide 15 of yesterdays Needham conf. Absolutely amazing results.....Zero cancer growth.

Recs

0
Member Avatar Stonesolidpicks (< 20) Submitted: 12/4/2009 5:53:37 PM : Outperform Start Price: $4.84 ONTY Score: -131.66

Cancer drug in Phase 3

Recs

0
Member Avatar mbs9 (< 20) Submitted: 8/27/2009 10:34:35 PM : Outperform Start Price: $5.57 ONTY Score: -150.40

it has some "hidden" gems ready to be announced

Recs

0
Member Avatar TMFBiologyFool (95.85) Submitted: 8/3/2009 2:37:24 PM : Outperform Start Price: $5.65 ONTY Score: -159.61

Promising drugs don't deserve $100 million market caps.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement